Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Virmani P, Busam K, Myskowski PL, Yang A, Magro C, Horwitz S. Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab. JAAD Case Rep. 2017;3(4):269-272.

Sederdahl BK, Yi J, Jerris R, Gillespie SE, Westblade L, Kraft CS, et al. The Residual Vaccine-preventable Burden of Rotavirus Disease. Pediatr Infect Dis J. 2017;36(8):780-781.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017;32(6):792-806.e7.

DeSimone RA, Wontakal SN, Lyashchenko AK, Schwartz J. Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child. J Clin Apher. 2017;32(6):571-573.

J Mulvey J, Matnani R, Cushing MM. Historical ABO blood group discrepancy: a blessing in disguise to unravel a medical identity theft. Transfusion. 2017;57(4):1096-1097.

Magro CM, Olson LC, Fulmer CG. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease. Ann Diagn Pathol. 2017;30:52-58.

Fan J, Zhang H, Nguyen DT, Lyon CJ, Mitchell CD, Zhao Z, et al. Rapid diagnosis of new and relapse tuberculosis by quantification of a circulating antigen in HIV-infected adults in the Greater Houston metropolitan area. BMC Med. 2017;15(1):188.

Cheng E, Ko D, Nguyen M, Moo T-, Andreopoulou E, Hoda SA, et al. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. Am J Surg Pathol. 2017;41(9):1275-1282.